NCT04167813 - Trial of Ondansetron as a Parkinson's HAllucinations Treatment | Biotech Hunter

Enrollment

168

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

August 30, 2024

Study Completion Date

August 30, 2024

Conditions

Parkinson's HallucinationsDementia With Lewy Bodies

Interventions

DRUG

Ondansetron 8mg or matched placebo tablets

"Participants will take one tablet daily in weeks 1 and 2, two tablets daily in weeks 3 and 4 and 3 tablets daily in weeks 5 and 6.~Dose escalation will be guided by tolerability, through telephone safety monitoring prior to each dose increase"

Trial Locations (23)

Unknown

Grampian, Aberdeen

Betsi Cadwaladr, Bangor

Pennine, Bury

Addenbrookes, Cambridge

Dartford, Dartford

Tayside, Dundee

Glasgow, Glasgow

Barking, London

Bart's Health, London

Imperial College NHS, London

Lewisham, London

Luton & Dunstable, London

UCLH NHS foundation trust, London

Newcstle, Newcastle

Anuerin Bevan, Newport

Northumbria, North Shields

Oxford, Oxford

North West Anglia, Peterborough

Dorset, Poole

Cornwall, Redruth

Salford, Salford

North Midlands, Stoke

Sherwood Forest, Sutton in Ashfield